eISSN: 2221-6197 DOI: 10.31301/2221-6197

Biomics

Archive

Indexing
  1. Biomics
  2. →
  3. 2020
  4. →
  5. Volume 12, no. 4
  6. →
  7. The use of pharmacogenetic testing for statins in the Republican Medical Genetic Center of the Republic of Bashkortostan

The use of pharmacogenetic testing for statins in the Republican Medical Genetic Center of the Republic of Bashkortostan

Year: 2020

Pages: 464-468

Number: Volume 13, issue 4

DOI: https://doi.org/10.31301/2221-6197.bmcs.2020-39

Topic: Article

Authors: Khusainova R.I.!, Akhmetgaleeva A.F., Sultanova R.I., Akhmetova V.L., Zaitseva O.E., Minniakhmetov I.R.

Download pdf

Summary:

Statins are a group of hypolipidemic drugs used to treat hypercholesterolemia. However undesirable drug reactions, such as an asymptomatic increase in transaminase activity; stomach ache; myalgia and myopathy, rhabdomyolysis is possible because of statins. The incidence of the development of myalgias and myopathies ranges from 2-3% to 10-25%. The variability of the pharmacological response depends on the polymorphic gene variants, the products of which are responsible for pharmacokinetic and pharmacodynamic processes. DNA testing of patients using statins was carried out at the Republican Medical Genetic Center. It was determined the polymorphic variant SLCO1B1 * 5 (rs4149056). DNA samples were examined from 42 patients, aged 6-73 years. As a result of DNA testing, a homozygous variant of the SLCO1B1 gene, the “wild” TT genotype, was detected in 28 (66.66%) patients. These patients have a low risk of liver and striated muscles damages. The maximum permissible dosage of drugs should not be exceeded. The heterozygous TC genotype of the SLCO1B1 gene, which promotes the production of a protein with reduced activity was found in 9 (21.43%) patients. It can be concluded that standard dosage of statins cause developing liver and striated muscle damage. The maximum permissible dose of drugs is reduced. A homozygous variant of the SLCO1B1 gene (genotype CC), was observed in 4 (9.52%) people. In this case the risk of developing myopathies reaches 60%, therefore, the dose of statins should be minimal. The results of the study indicate the need to use pharmacological DNA testing in clinical practice.

Keywords:

Pharmacogenetics, DNA testing, statins

References:

  1. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3- methylglutaryl coenzyme a reductase by ML-236a and ML-236b fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976. V. 72. P. 323–326.
  2. Rossijskie rekomendacii RKO, NOA, RosOKR. VI peresmotr. Diagnostika i korrekcija narushenij lipidnogo obmena s cel'ju profilaktiki i lechenija ateroskleroza. Moskva. 2017. RCS, NSA, RSCR Guidelines. VI revision. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis // Moscow. 2017 [Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis - Guidelines. VI revision] (In Russian)
  3. Kazi, D. S., Penko, J. M., & Bibbins-Domingo, K. Statins for Primary Prevention of Cardiovascular Disease. Medical Clinics of North America. 2017. V 101(4). P. 689–699.
  4. Catapano A.L., Graham I., De Backer G. et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016. V.37(39). P. 2999- 3058. doi.org/10.1093/eurheartj/ehw272
  5. Canestaro W.J., Brooks D.G., Pers D.C. Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine. 2012. №2. P. 158– 174.
  6. Dyadyk A.I., Kugler T.E., Suliman Y.V., Zborovskyy S.R., Zdykhovskaya I.I. Statin adverse effects: mechanisms, diagnosis, prevention and management. The Russian Archives of Internal Medicine. 2018. V.8. №4. P. 266-276. [In Russian]. DOI: 10.20514/2226-6704-2018-8-4-266-276
  7. Hagenbuch B., Meier P. J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflügers Archiv. 2004. V. 447. № 5. P. 653-665.DOI 10.1007/s00424-003-1168-y
  8. Crowe A, Zheng W, Miller J, et al. Characterization of Plasma Membrane Localization and Phosphorylation Status of Organic Anion Transporting Polypeptide (OATP) 1B1 c.521 T>C Nonsynonymous Single-Nucleotide Polymorphism. Pharm Res. 2019. V. 36. №7. P.101. doi:10.1007/s11095-019-2634-3
  9. Kazakov R.E., Evteev V.A., Muslimova O.V., Mazerkina I.A., Demchenkova E.Ju Znachenie geneticheskih faktorov v prognozirovanii pobochnogo dejstvija statinov. Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanij. 2016. № 8. P. 691-698. [The significance of genetic factors in predicting the side effects of statins] (In Russian)
  10. Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T>C polymorphism associated with rosuvastatininduced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017. V. 73. №11. P. 1409-1416. doi:10.1007/s00228-017-2318-z
  11. Du Y, Wang S, Chen Z, Sun S, Zhao Z, Li X. Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis. Curr Pharm Des. 2018. V. 24. №34. P.4044-4050. doi:10.2174/1381612825666181219163534
  12. Sychev DA, Shuev GN, Prokofiev AB. Applied aspects of SLCO1B1 pharmacogenetic testing for predicting of statin-induced myopathy and personalization of statins therapy. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2013. V9, №6. P.698– 700 doi: 10.20996/1819-6446-2013-9-6-698-700 (In Russian)
  13. Pasanen M.K1, Neuvonen P.J., Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008. V.9(1). P. 19–33.
Download pdf
up
eISSN: 2221-6197 DOI: 10.31301/2221-6197